Will FDA Inspection Observations Fog Speculated Claris Deal?
This article was originally published in The Pink Sheet Daily
Executive Summary
Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with chatter about a deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.